SANTA MONICA, Calif. , Oct. 10, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that Chief Executive Officer, Roger Crystal , M.D., and Chief Scientific

SANTA MONICA, Calif. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that it will present at the 2019 Cantor Global Healthcare Conference , taking

SANTA MONICA, Calif. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced the appointments of Aziz Mottiwala as Opiant’s Chief Commercial Officer, and

SANTA MONICA, Calif. , Aug. 27, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, will present at the following upcoming investor conferences: 2019 Wells Fargo Securities

SANTA MONICA, Calif. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today reported financial results for the second quarter and six months ended June 30, 2019 and

SANTA MONICA, Calif. , July 30, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it will report its financial results for the second quarter and six months

SANTA MONICA, Calif. , July 23, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it has signed an agreement with Sanofi (NYSE:SNY) to manufacture Opiant’s

SANTA MONICA, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today reported financial results for the three months ended March 31, 2019 , and provided a

SANTA MONICA, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it will report its financial results for the first quarter ended March 31,

Data published online in the Journal of Pharmacology and Experimental Therapeutics SANTA MONICA, Calif. , April 08, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that